Clinical trials
Phase 2 Eye Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Terminated | 6 |
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adverum Biotechnologies, Inc. | 3 |
| Neurotech Pharmaceuticals | 3 |
| Amakem, NV | 2 |
| Gyroscope Therapeutics Limited | 2 |
| LENZ Therapeutics, Inc | 2 |
| Nanoscope Therapeutics Inc. | 2 |
| Oraya Therapeutics, Inc. | 2 |
| Alcon Research | 1 |
| Alkahest, Inc. | 1 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Eye Diseases | 42 |
| Retinal Diseases | 17 |
| Retinal Degeneration | 10 |
| Macular Degeneration | 9 |
| Retinitis Pigmentosa | 5 |
| Dry Eye Syndromes | 4 |
| Blindness | 3 |
| Corneal Diseases | 3 |
| Edema | 3 |
| Eye Diseases, Hereditary | 3 |
Trials
Showing 76 to 42 of 42. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.